Announcement PDF RNS Number : 6553Z Fusion Antibodies PLC 15 September 2022 Fusion Antibodies plc ("Fusion" or the "Company") Grant of options Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company has today granted 1,480,800 options (the "Options") over ordinary shares of 4 pence each in the Company ("Ordinary Shares") to certain Executive Directors and employees of the Company. The Options were granted pursuant to the Fusion Antibodies EMI and Unapproved Employee Share Option Scheme (the "Scheme"), adopted by the Company on 11 December 2017. The Options have an exercise price of 47.50 pence per Option, being the closing mid-market price of an Ordinary Share on 14 September 2022, the day prior to grant. The Options will vest equally over a three-year period, with one third of the Options vesting on each anniversary following the grant date and subject to continuing employment only. Once vested, the Options can be exercised for a period of ten years from the grant date. 200,000 of the Options have been granted to the following Executive Directors of the Company: Number of Options granted Existing options over Ordinary Shares held Total Options over Ordinary Shares held following grant Richard Buick, CSO 100,000 180,000 280,000 James Fair, CFO 100,000 275,000 375,000 Name Following the grant of the Options, the Company has options in issue over a total of 2,542,883 Ordinary Shares, representing 9.77 per cent. of the Company's issued share capital. 2,439,133 of the options have been issued pursuant to the Scheme and the balance of 103,750 options have been issued outside of the scheme. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1 a) 2 a) b) 3 a) b) 4 Details of the person discharging managerial responsibilities / person closely associated Name Richard Buick Reason for the notification Position/status Director - Chief Scientific Officer Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name Fusion Antibodies plc LEI 213800KBAYRC9VOQ9V39 Details of the transaction(s): section to be repeated for (i) each type a) of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the financial Options over ordinary shares of 4p each in instrument, type of Fusion Antibodies plc instrument Identification code b) Nature of the transaction c) Price(s) and volume(s) d) e) f) 1 a) 2 a) b) 3 a) b) 4 a) Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction b) Nature of the transaction c) Price(s) and volume(s) e) f) Price(s) Volume(s) 47.50p 100,000 N/A 15 September 2022 Outside a trading venue Details of the person discharging managerial responsibilities / person closely associated Name James Fair Reason for the notification Position/status Director - Chief Financial Officer Initial notification Initial notification /Amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor Name Fusion Antibodies plc LEI 213800KBAYRC9VOQ9V39 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the financial Options over ordinary shares of 4p each in instrument, type of Fusion Antibodies plc instrument Identification code d) Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 Grant of options over ordinary shares Aggregated information - Aggregated volume - Price Date of the transaction Place of the transaction Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 Grant of options over ordinary shares Price(s) Volume(s) 47.50p 100,000 N/A 15 September 2022 Outside a trading venue Enquiries: Fusion Antibodies plc Adrian Kinkaid, Chief Executive Officer James Fair, Chief Financial Officer www.fusionantibodies.com Via Walbrook PR Allenby Capital Limited James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke (Sales and Corporate Broking) Walbrook PR Anna Dunphy Paul McManus Tel: +44 (0)20 3328 5656 Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com Mob: +44 (0)7876 741 001 Mob: +44 (0)7980 541 893 About Fusion Antibodies plc Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHFLFSSAIIELIF